PRELUDE THERAPEUTICS INC (PRLD) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 79.80M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 79.80M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 79.80M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 79.80M | (m) | (m) |
| 2026-03-31 | 79.65M | (m) | (m) |
| 2025-12-31 | 63.00M | (m) | (m) |
| 2025-09-30 | 62.87M | (m) | (m) |
| 2025-06-30 | 56.60M | (m) | (m) |
| 2025-03-31 | 56.46M | (m) | (m) |
| 2024-12-31 | 55.15M | (m) | (m) |
| 2024-09-30 | 55.04M | (m) | (m) |
| 2024-06-30 | 55.02M | (m) | (m) |
| 2024-03-31 | 54.93M | (m) | (m) |
| 2023-12-31 | 54.92M | (m) | (m) |
| 2023-09-30 | 54.83M | (m) | (m) |
| 2023-06-30 | 54.81M | (m) | (m) |
| 2023-03-31 | 47.96M | (m) | (m) |
| 2022-12-31 | 47.91M | (m) | (m) |
| 2022-09-30 | 47.86M | (m) | (m) |
| 2022-06-30 | 47.83M | (m) | (m) |
| 2022-03-31 | 47.70M | (m) | (m) |
| 2021-12-31 | 47.63M | (m) | (m) |
| 2021-09-30 | 47.22M | (m) | (m) |
| 2021-06-30 | 47.09M | (m) | (m) |
| 2021-03-31 | 46.96M | (m) | (m) |
| 2020-12-31 | 46.59M | (m) | (m) |
| 2020-09-30 | 43.70M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |